Type 2 Diabetes | Unmet Need | Oral Medications | US/EU | 2021
The oral type 2 diabetes (T2D) drug market is expected to grow, fueled by rising prevalence and an increasing aging population. Owing to the risk of proteinuria, cardiovascular (CV) complications, and kidney disease associated with T2D, a great unmet need exists for affordable oral drugs that can safely and effectively manage this disease over the long term. The sodium-glucose co-transporter-2 (SGLT-2) inhibitors, such as AstraZeneca’s Farxiga / Forxiga and Novo Nordisk’s Rybelsus (an oral glucagon-like peptide-1 [GLP-1] receptor agonist), provide CV and renal benefits, along with weight loss. However, the physical and financial impacts of T2D continue to increase, highlighting the need for more-effective and more-tolerable drug treatments.
QUESTIONS ANSWERED
- How do endocrinologists rate current T2D oral drug classes, such as the DPP-IV inhibitors, SGLT-2 inhibitors, and meglitinides?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How satisfied are endocrinologists with the performance of Rybelsus, the only oral GLP-1 receptor agonist, in terms of the studied attributes?
- What trade-offs across different clinical attributes and prices are acceptable to U.S. and European physicians for a hypothetical new T2D drug?
PRODUCT DESCRIPTION
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 33 European endocrinologists fielded in March 2021.
Key companies: Novo Nordisk, Merck, AstraZeneca, Boehringer Ingelheim, Eli Lilly
Key drugs: DPP-IV inhibitors, oral GLP-1 receptor agonist, meglitinides, SGLT-2 inhibitors
